Ashok Leyland has submitted the confirmation certificate received from Integrated Registry Management Services Private Limited, the Registrar and Share Transfer Agent (RTA), pertaining to the quarter ended September 30, 2025. This certificate is in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The submission confirms adherence to regulatory requirements for the specified period.

Certificate of Compliance

Ashok Leyland confirms the receipt and submission of the certificate from Integrated Registry Management Services Private Limited concerning regulatory compliance. This certificate pertains to the quarter ended September 30, 2025, and confirms adherence to stipulated guidelines.

Regulatory Confirmation

The submitted certificate ensures compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This affirms that all shares mentioned in the certificate received for dematerialization are listed on the stock exchanges, where the earlier issued shares were listed.

Key Confirmation Details

The confirmation also includes that any mutilated or cancelled certificates of security, if any, have been duly verified and immediately substituted with the depository’s name as the registered owner. This action was completed within 15 days of receiving the certificate of security from the participant. Details of shares dematerialized/rematerialized during the quarter have been furnished to all relevant stock exchanges.

Source: BSE

Container Corporation of India (CONCOR) has announced the redesignation of Shri. Shrikant V. Janbandhu, Executive Director (C&O). This change in senior management has been formalized in an order dated October 6, 2025. The announcement provides details of the internal restructuring and its effect on leadership roles within the organization.

Senior Management Update

Container Corporation of India (CONCOR) has announced a change in its senior management. Effective October 6, 2025, Shri. Shrikant V. Janbandhu, previously serving as Executive Director (C&O), has been redesignated.

Leadership Transition

The company communicated this change as part of its ongoing organizational adjustments. The official order confirms the internal restructuring and its impact on key leadership positions.

Source: BSE

SRF Limited has submitted a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2025. The certificate, provided by KFIN Technologies Limited (“RTA”) on October 2, 2025, ensures adherence to regulatory requirements regarding dematerialization and rematerialization of securities.

Compliance Confirmation

SRF Limited has formally announced its compliance with essential regulatory standards concerning depositories and participants. This announcement pertains specifically to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018.

Details of Compliance

The compliance certificate, which validates the company’s adherence to these regulations, was issued by KFIN Technologies Limited on October 2, 2025. It confirms that all requirements for the quarter ending September 30, 2025, have been met. This includes the proper handling of securities that have been dematerialized or rematerialized as required by regulatory standards.

KFin Technologies’ Role

As the Registrars, Share Transfer, and Depository Services agents for SRF Limited, KFin Technologies Limited certified that the details of securities dematerialized/rematerialized during the specified period have been furnished to all the Stock Exchanges where the company’s shares are listed. This ensures transparency and compliance within the framework of the SEBI regulations.

Source: BSE

Vedanta Limited has announced the issuance of a certificate concerning the handling of securities during the quarter ended September 30, 2025. The certificate, dated October 6, 2025, confirms compliance with regulations related to depositories and participants, ensuring proper dematerialization processes. This announcement highlights Vedanta’s adherence to regulatory standards and efficient management of its securities.

Compliance Confirmation

Vedanta Limited has received and processed the necessary certificate related to securities for the quarter ending September 30, 2025. This certificate, issued on October 6, 2025, confirms that all activities related to the dematerialization of securities have been handled in accordance with regulatory requirements.

Details of the Certificate

The certificate, provided by KFin Technologies Limited, the Registrar & Share Transfer Agent, attests that all securities received for dematerialization during Q2 FY26 have been duly processed. This includes confirmation to the depositories and proper listing on stock exchanges where the securities are traded. The company also confirms that certificates received for dematerialization have been mutilated and cancelled following verification, and the register of members has been updated accordingly.

Source: BSE

Zydus Lifesciences has received approval from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg dosages. These tablets, a synthetic form of the thyroid hormone T3, are primarily used for treating hypothyroidism. The annual sales for Liothyronine tablets in Canada were CAD 10.9 million as of June 2025. This approval allows Zydus to expand its presence in the Canadian pharmaceutical market.

Canadian Market Expansion

Zydus Lifesciences Limited has secured Notice of Compliance (NOC) from Health Canada for its generic version of Liothyronine tablets, available in 5 mcg and 25 mcg strengths. The approval, announced on October 6, 2025, signifies a key regulatory milestone that helps expand Zydus’s reach.

Liothyronine Tablets Overview

Liothyronine tablets are a synthetic form of the thyroid hormone T3 (triiodothyronine). The medication is primarily prescribed for treating hypothyroidism. With this approval, Zydus aims to address a crucial need in the Canadian market.

Market Performance and Manufacturing

Zydus will manufacture these tablets at its plant in Ahmedabad SEZ. According to IQVIA data, the annual sales of Liothyronine tablets in Canada amounted to CAD 10.9 million as of June 2025, indicating a considerable market opportunity for Zydus following this regulatory approval.

Source: BSE

CreditAccess Grameen has issued a certificate confirming the dematerialization/rematerialization of securities for the quarter ended September 30, 2025. The details have been furnished to the Stock Exchanges where the company’s shares are listed. KFin Technologies Limited, the Registrar and Share Transfer Agent, has also provided confirmation.

Compliance Confirmation

CreditAccess Grameen confirms compliance regarding the dematerialization and rematerialization of securities. This announcement pertains to the requirements outlined for depositories and participants. The confirmation is specifically for the period ending September 30, 2025.

Details of Compliance

The company confirms that all details of securities that have been dematerialized or rematerialized during the quarter ending September 30, 2025, have been duly furnished to the stock exchanges. KFin Technologies Limited, the registrar, share transfer, and depository services agent, has also issued a confirming letter, which is enclosed.

Source: BSE

Clean Science and Technology Limited confirms that its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, received no requests for dematerialization of securities during the quarter ended September 30, 2025. This announcement, dated October 6, 2025, was made to the BSE and NSE to comply with regulatory requirements.

Compliance Confirmation

Clean Science and Technology Limited announced on October 6, 2025, that no securities were received for dematerialization during the period.

Details of the Confirmation

According to the certificate received from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent of Clean Science, there were no requests for dematerialization during the Q2 2025 quarter, which concluded on September 30, 2025.

Source: BSE

REC Limited has issued a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, received from Alankit Assignments Limited, confirms compliance for the quarter ended September 30, 2025. This announcement ensures information and record maintenance.

Compliance Certificate Issued

REC Limited has secured a certificate concerning SEBI’s Depositories and Participants Regulations for Q2 FY26, ensuring adherence to regulatory standards.

Details of Compliance

The certificate, as per Regulation 74(5), has been received from the Registrar and Transfer Agent, Alankit Assignments Limited, and pertains to the quarter ending September 30, 2025. It verifies the dematerialization requests and related processes are in compliance. This disclosure is for informational purposes and record keeping.

Source: BSE

Jaiprakash Power Ventures has received a certificate regarding the dematerialization of securities for the quarter ended September 30, 2025. The certificate confirms that the securities received for dematerialization have been mutilated and cancelled after due verification. The depository’s name has been substituted in the records as the registered owner.

Dematerialization Certificate

Jaiprakash Power Ventures Limited has announced the receipt of a certificate pertaining to the dematerialization of securities. This announcement relates to the quarter that concluded on September 30, 2025.

Details of Compliance

The certificate, as provided by Alankit Assignments Limited, the Registrar and Share Transfer Agent, confirms that all securities received for dematerialization have undergone the necessary procedures. These include mutilation and cancellation following thorough verification. The records now reflect the depository as the registered owner, completing the dematerialization process.

Source: BSE

Metropolis Healthcare announced a robust 23% year-on-year revenue growth at the consolidated level for Q2 FY26 (July-September 2025). This growth was driven by strong performance in preventive health check-ups and wellness offerings. The company’s diversified portfolio and strategic acquisitions contributed to its resilience against seasonal headwinds. Metropolis is debt-free with a net cash surplus of approximately INR 55 crores.

Q2 FY26 Performance Highlights

Metropolis Healthcare has reported strong financial results for the second quarter of fiscal year 2026, showcasing significant growth and strategic advancements. Key highlights include:

• Revenue Growth: Approximately 23% year-on-year increase, including revenues from Core Diagnostics, Scientific Pathology, and other acquired entities.

Segment Performance

Specific segments within Metropolis Healthcare demonstrated notable growth:

• TruHealth Wellness: Recorded year-on-year growth of approximately 25%.
• Specialty Segments: Experienced year-on-year growth of approximately 36%.

Core Diagnostics and Acquisitions

The company’s strategic initiatives in diagnostics and pathology have yielded positive results:

• Core Diagnostics: Improved from a breakeven position in Q4 FY25 to a high single-digit margin in Q2 FY26, driven by operational efficiencies and synergies.
• Recent Acquisition: The acquisition of Dr. RS Patil’s Ambika Pathology Laboratory, Kolhapur, effective September 18, 2025, strengthens Metropolis’s leadership position in the Kolhapur region.

B2C and B2B Revenue

• B2C Revenue: Registered a year-on-year growth of around 16%.
• B2B Revenue: Grew by approximately 34%, driven by higher contributions from Core Diagnostics.

Financial Position

Metropolis Healthcare maintains a strong financial footing:

• Debt-Free Status: The company is debt-free on a consolidated basis.
• Cash Surplus: Has a net cash surplus of approximately INR 55 crores.

Standalone Performance

• Revenue Growth: Grew by approximately 12% year-on-year, driven by increased patient and test volumes, a favorable shift in product mix, and improved realizations.
• EBITDA Margins: Demonstrated quarter-on-quarter improvement, reflecting resilient business operations and strong operating leverage. Margins also showed a positive year-on-year trend.

Source: BSE